Is it worth buying CVS Health stock at a price of $69.94? If this question is on your mind, make sure to check out the fundamentals of this Pharmaceutical Retail large-cap company:
-
CVS Health has logged a -26.0% 52 week change, compared to 21.0% for the S&P 500
-
CVS has an average analyst rating of buy and is -22.75% away from its mean target price of $90.54 per share
-
Its trailing earnings per share (EPS) is $2.14, which brings its trailing Price to Earnings (P/E) ratio to 32.7. The Consumer Staples sector's average P/E ratio is 24.36
-
The company's forward earnings per share (EPS) is $8.6 and its forward P/E ratio is 8.1
-
The company has a Price to Book (P/B) ratio of 1.23 in contrast to the Consumer Staples sector's average P/B ratio is 4.29
-
The current ratio is currently 0.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
CVS has reported YOY quarterly earnings growth of -35.4% and gross profit margins of 0.2%
-
The company's free cash flow for the last fiscal year was $20.78 Billion and the average free cash flow growth rate is 0.0%
-
CVS Health's revenues have an average growth rate of 0.0% with operating expenses growing at -15.9%. The company's current operating margins stand at 5.1%